MetaVia Inc. (Nasdaq: MTVA) is building momentum following positive Phase 2a results for its oral GPR119 agonist, DA-1241. The company has announced a new research collaboration with Syntekabio, an AI-powered drug discovery firm, to explore new indications for DA-1241 using Syntekabio’s DeepMatcher platform.
DA-1241 has already shown promise in patients with metabolic dysfunction-associated steatohepatitis (MASH), delivering favorable safety, hepatoprotective, and glucose-regulating results in a 16-week Phase 2a study. Now, MetaVia aims to broaden the value of DA-1241 by using DeepMatcher to screen over 1,700 validated protein targets. The goal is to uncover additional diseases where the candidate may be effective while minimizing off-target risks.
DA-1241’s key differentiator is its ability to activate gut hormones like GLP-1, GIP, and PYY, offering benefits for both liver and metabolic health. The collaboration reflects MetaVia’s strategy of leveraging technology to accelerate discovery, expand pipeline potential, and deliver value in the competitive metabolic disease space.
MetaVia expects initial insights from the collaboration later this year as it continues to advance both DA-1241 and its lead obesity candidate, DA-1726.
The post MetaVia Accelerates Metabolic Disease Pipeline with Syntekabio AI Collaboration appeared first on PRISM MarketView.
